Overall, disease-specific survival is up for patients who undergo tonsil resection rather than biopsy.
Task force says more work is needed to see if tests can accurately detect oral cancer and improve outcomes.
For patients with papillary thyroid cancer (PTC), the presence of the BRAF V600E mutation is associated with increased cancer-related mortality.
Adding erlotinib did not increase treatment toxicity in squamous cell carcinoma of the head and neck, but it also did not improve survival.
HNSCC is the seventh most common form of cancer in the United States. However, other than an association with HPV, no validated molecular profile of the disease has been established. By analyzing data from DNA microarrays, a study has confirmed the presence of four molecular classes of the disease.
Using a classification strategy, all patients were event-free at a median 71 months of follow-up.
A new drug combination shows promise in reducing the risk of developing squamous cell carcinoma of the head and neck (SCCHN) for patients with advanced oral precancerous lesions.
Therapeutic vaccines for mucosal cancers may work best when administered directly at the site of those tumors rather than elsewhere.
The experimental drug selumetinib increased iodine uptake and retention in a subgroup of patients with radioiodine-resistant thyroid cancer.
Although a large majority of head and neck cancers have a deregulation of the PI3K/AKT/mTOR pathway, recently published data indicates that deregulation of this pathway does not necessarily signify that the tumor is dependent on it for survival and progression.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|